Last reviewed · How we verify
rPA102 Vaccine
rPA102 Vaccine is a Biologic drug developed by VaxGen. It is currently in Phase 1 development.
At a glance
| Generic name | rPA102 Vaccine |
|---|---|
| Sponsor | VaxGen |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Trial of rPA-102 Vaccine in Healthy Adult Volunteers (PHASE2)
- Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rPA102 Vaccine CI brief — competitive landscape report
- rPA102 Vaccine updates RSS · CI watch RSS
- VaxGen portfolio CI
Frequently asked questions about rPA102 Vaccine
What is rPA102 Vaccine?
rPA102 Vaccine is a Biologic drug developed by VaxGen.
Who makes rPA102 Vaccine?
rPA102 Vaccine is developed by VaxGen (see full VaxGen pipeline at /company/vaxgen).
What development phase is rPA102 Vaccine in?
rPA102 Vaccine is in Phase 1.
Related
- Manufacturer: VaxGen — full pipeline
- Compare: rPA102 Vaccine vs similar drugs
- Pricing: rPA102 Vaccine cost, discount & access